Psyched: Compass Joins Nasdaq, Field Trip Goes Public, MindMed Begins Trials, ATAI Launches MDMA Subsidiary
Compass Pathways Files for an IPO at NASDAQ
UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange.
The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol CMPS.
